pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
341
stories
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 31, 26
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
fiercebiotech
Jul 30, 26
Capricor’s data clash and a fugitive in the C-suite
stat
Jul 29, 26
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
Jul 29, 26
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
Jul 28, 26
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
Jul 28, 26
STAT+: Three questions with Whoop’s new CMO
stat
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
Jul 28, 26
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
Jul 28, 26
Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
endpoints
Jul 28, 26
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
Jul 28, 26
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
stat
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 24, 26
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
Jul 23, 26
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 23, 26
STAT+: European regulators take steps to bolster clinical trial transparency
stat
Jul 23, 26
STAT+: Popular insulin product enters shortage as other pens leave market
stat
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
STAT+: What’s in the last-minute flurry of health care bills?
stat
Jul 23, 26
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 23, 26
STAT+: HHS to convene experts on standards for clinical AI
stat
Jul 23, 26
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 23, 26
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
Jul 23, 26
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near
endpoints
Jul 23, 26
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
← prev
page 7 of 12
next →
